Implications of the paradigm shift in management of Helicobacter pylori infections.

IF 4.2 3区 医学
Therapeutic Advances in Gastroenterology Pub Date : 2023-03-18 eCollection Date: 2023-01-01 DOI:10.1177/17562848231160858
David Y Graham
{"title":"Implications of the paradigm shift in management of <i>Helicobacter pylori</i> infections.","authors":"David Y Graham","doi":"10.1177/17562848231160858","DOIUrl":null,"url":null,"abstract":"<p><p>The recent availability of susceptibility testing for <i>Helicobacter pylori</i> infections in the United Sates has resulted in paradigm shifts in the diagnosis, therapy, and follow-up of <i>H. pylori</i> infections. Here, we reviewed the English literature concerning changes in <i>H. pylori</i> diagnosis and therapy with an emphasis on the last 3 years. We focus on the new methods that offer rapid and convenient susceptibility testing using either invasive (endoscopic) or noninvasive (stool) methods of obtaining test material. We also discuss the implications of this availability on therapy and follow-up after therapy. The approach to therapy was categorized into four groups: (1) therapies that can be used empirically, (2) therapies that should be restricted to those that are susceptibility-based, (3) potentially effective therapies that have yet to be optimized for local use, and (4), therapies that contain unneeded antibiotics that should not be prescribed. The most convenient and efficient method of susceptibility testing is by using reflexive stool testing in which if the sample is positive, it is automatically also used for determination of susceptibility. Reflexive testing can also be done via reflexive ordering (e.g., for all positive urea breath tests). The post therapy test-of-cure has emerged as a critical component of therapy as it not only provides feedback regarding treatment success but when combined with susceptibility testing also provide evidence regarding the cause of failure (e.g., poor adherence <i>versus</i> emergence of resistance during therapy. Susceptibility testing has made even the most current <i>H. pylori</i> guidelines for diagnosis and therapy generally obsolete. Clarithromycin, metronidazole, and levofloxacin triple therapies should only be administered as susceptibility-based therapy. Regimens containing unneeded antibiotics should not be given. We provide recommendations regarding the details and indications for all current therapies.</p>","PeriodicalId":23022,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"16 ","pages":"17562848231160858"},"PeriodicalIF":4.2000,"publicationDate":"2023-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c4/bc/10.1177_17562848231160858.PMC10026128.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848231160858","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The recent availability of susceptibility testing for Helicobacter pylori infections in the United Sates has resulted in paradigm shifts in the diagnosis, therapy, and follow-up of H. pylori infections. Here, we reviewed the English literature concerning changes in H. pylori diagnosis and therapy with an emphasis on the last 3 years. We focus on the new methods that offer rapid and convenient susceptibility testing using either invasive (endoscopic) or noninvasive (stool) methods of obtaining test material. We also discuss the implications of this availability on therapy and follow-up after therapy. The approach to therapy was categorized into four groups: (1) therapies that can be used empirically, (2) therapies that should be restricted to those that are susceptibility-based, (3) potentially effective therapies that have yet to be optimized for local use, and (4), therapies that contain unneeded antibiotics that should not be prescribed. The most convenient and efficient method of susceptibility testing is by using reflexive stool testing in which if the sample is positive, it is automatically also used for determination of susceptibility. Reflexive testing can also be done via reflexive ordering (e.g., for all positive urea breath tests). The post therapy test-of-cure has emerged as a critical component of therapy as it not only provides feedback regarding treatment success but when combined with susceptibility testing also provide evidence regarding the cause of failure (e.g., poor adherence versus emergence of resistance during therapy. Susceptibility testing has made even the most current H. pylori guidelines for diagnosis and therapy generally obsolete. Clarithromycin, metronidazole, and levofloxacin triple therapies should only be administered as susceptibility-based therapy. Regimens containing unneeded antibiotics should not be given. We provide recommendations regarding the details and indications for all current therapies.

Abstract Image

Abstract Image

Abstract Image

幽门螺旋杆菌感染管理模式转变的影响。
最近,美国推出了幽门螺杆菌感染药敏试验,导致幽门螺杆菌感染的诊断、治疗和随访模式发生了转变。在此,我们回顾了有关幽门螺杆菌诊断和治疗变化的英文文献,重点是最近三年的情况。我们的重点是使用侵入性(内窥镜)或非侵入性(粪便)方法获取检测材料,提供快速方便的药敏试验的新方法。我们还讨论了这种可用性对治疗和治疗后随访的影响。治疗方法分为四类:(1) 可根据经验使用的疗法;(2) 应仅限于基于药敏试验的疗法;(3) 在本地使用时尚未优化的潜在有效疗法;(4) 含有不需要的抗生素且不应处方的疗法。最方便有效的药敏试验方法是使用反射性粪便检测,如果样本呈阳性,则自动用于药敏测定。反射性检测也可通过反射性下单(如所有尿素呼气试验阳性)来完成。治疗后的治愈试验已成为治疗的重要组成部分,因为它不仅能提供治疗成功与否的反馈,而且与药敏试验相结合,还能提供失败原因的证据(如治疗过程中依从性差或出现抗药性)。即使是最新的幽门螺杆菌诊断和治疗指南,药敏试验也已普遍过时。克拉霉素、甲硝唑和左氧氟沙星三联疗法只能作为基于药敏试验的疗法使用。不应使用含有不需要的抗生素的治疗方案。我们就目前所有疗法的细节和适应症提出了建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology Medicine-Gastroenterology
自引率
2.40%
发文量
103
期刊介绍: Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信